



(51) International Patent Classification:

C07D 307/68 (2006.01) **A61K 31/341** (2006.01)
C07D 405/12 (2006.01) **A61P 17/10** (2006.01)
C07D 407/12 (2006.01)

(21) International Application Number:

PCT/US2010/040795

(22) International Filing Date:

1 July 2010 (01.07.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/224,042 8 July 2009 (08.07.2009) US

(71) Applicant (for all designated States except US): **VALO-COR THERAPEUTICS, INC.** [CA/CA]; P.O. Box 10424, Pacific Center, 13000-777 Dunsmuir Street, Vancouver, British Columbia V7Y 1K2 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DAYNARD, Timothy, Scott** [CA/CA]; 1836 West 62nd Avenue, Vancouver, British Columbia V6P 2G4 (CA). **WINTERS, Geoffrey, C.** [CA/CA]; #1-851 Keefer Street, Vancouver, British Columbia V6A 1Y8 (CA). **HUNT, David, W.C.** [CA/CA]; 12722 Beckett Road, Surrey, British Columbia V4A 2X1 (CA).

(74) Agents: **HAN, Hai** et al.; Seed Intellectual Property Law Group PLLC, Suite 5400, 701 Fifth Avenue, Seattle, WA 98104-7064 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS



(57) Abstract: This invention is directed to analogs of 5-(tetradecyloxy)-2-furancarboxylic acid (TOFA) and their use in the treatment of dermatological disorders or conditions characterized by sebaceous gland hyperactivity, such as acne and oily skin, and other dermatological disorders and conditions. This invention is also directed to pharmaceutical compositions comprising analogs of TOFA and a pharmaceutically acceptable excipient for dermatological or oral administration. Formula (I)